Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Rho-kinase inhibitors.

Fukumoto Y, Shimokawa H.

Handb Exp Pharmacol. 2013;218:351-63. doi: 10.1007/978-3-642-38664-0_14. Review.

PMID:
24092347
2.

Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors.

Fukumoto Y, Tawara S, Shimokawa H.

Tohoku J Exp Med. 2007 Apr;211(4):309-20. Review.

3.

[The role of Rho-kinase pathway on PAH].

Fukumoto Y, Shimokawa H.

Nihon Rinsho. 2008 Nov;66(11):2091-6. Review. Japanese.

PMID:
19051725
4.

Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension.

Raja SG.

Recent Pat Cardiovasc Drug Discov. 2012 Aug;7(2):100-4. Review.

PMID:
22670803
5.

RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension.

Barman SA, Zhu S, White RE.

Vasc Health Risk Manag. 2009;5:663-71. Review.

6.

Animal models of pulmonary hypertension: Rho kinase inhibition.

Firth AL, Choi IW, Park WS.

Prog Biophys Mol Biol. 2012 Aug;109(3):67-75. doi: 10.1016/j.pbiomolbio.2012.05.009. Review.

PMID:
22713173
7.

Role of Rho-kinase and its inhibitors in pulmonary hypertension.

Duong-Quy S, Bei Y, Liu Z, Dinh-Xuan AT.

Pharmacol Ther. 2013 Mar;137(3):352-64. doi: 10.1016/j.pharmthera.2012.12.003. Review.

PMID:
23261521
8.

Rho-kinase as a potential therapeutic target for the treatment of pulmonary hypertension.

Xing XQ, Gan Y, Wu SJ, Chen P, Zhou R, Xiang XD.

Drug News Perspect. 2006 Nov;19(9):517-22. Review.

PMID:
17220956
9.

The xanthine derivative KMUP-1 inhibits models of pulmonary artery hypertension via increased NO and cGMP-dependent inhibition of RhoA/Rho kinase.

Chung HH, Dai ZK, Wu BN, Yeh JL, Chai CY, Chu KS, Liu CP, Chen IJ.

Br J Pharmacol. 2010 Jun;160(4):971-86. doi: 10.1111/j.1476-5381.2010.00740.x.

10.

Fluoxetine inhibits monocrotaline-induced pulmonary arterial remodeling involved in inhibition of RhoA-Rho kinase and Akt signalling pathways in rats.

Wang HM, Wang Y, Liu M, Bai Y, Zhang XH, Sun YX, Wang HL.

Can J Physiol Pharmacol. 2012 Nov;90(11):1506-15. doi: 10.1139/y2012-108.

PMID:
23181278
11.

The role of the RhoA/rho-kinase pathway in pulmonary hypertension.

Nossaman BD, Kadowitz PJ.

Curr Drug Discov Technol. 2009 Mar;6(1):59-71. Review.

PMID:
19275543
12.

Rho kinase-mediated vasoconstriction in rat models of pulmonary hypertension.

Oka M, Homma N, McMurtry IF.

Methods Enzymol. 2008;439:191-204. doi: 10.1016/S0076-6879(07)00415-6.

PMID:
18374166
13.

Development of Rho-kinase inhibitors for cardiovascular medicine.

Shimokawa H, Rashid M.

Trends Pharmacol Sci. 2007 Jun;28(6):296-302. Review.

PMID:
17482681
14.

Rho-kinase inhibitors show promise in pulmonary hypertension.

Doggrell SA.

Expert Opin Investig Drugs. 2005 Sep;14(9):1157-9. Review.

PMID:
16144499
15.

[Update: Preclinical developments for the treatment of pulmonary arterial hypertension].

Janssen W, Ghofrani HA, Weissmann N, Grimminger F, Schermuly RT.

Dtsch Med Wochenschr. 2009 Aug;134 Suppl 5:S157-9. doi: 10.1055/s-0029-1225313. Review. German.

PMID:
19718604
16.

Emerging therapies for the treatment of pulmonary hypertension.

Stenmark KR, Rabinovitch M.

Pediatr Crit Care Med. 2010 Mar;11(2 Suppl):S85-90. doi: 10.1097/PCC.0b013e3181c76db3. Review.

PMID:
20216170
17.
18.

Targeted therapies in pulmonary arterial hypertension.

Montani D, Chaumais MC, Guignabert C, Günther S, Girerd B, Jaïs X, Algalarrondo V, Price LC, Savale L, Sitbon O, Simonneau G, Humbert M.

Pharmacol Ther. 2014 Feb;141(2):172-91. doi: 10.1016/j.pharmthera.2013.10.002. Review.

PMID:
24134901
19.

Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension.

Gupta V, Gupta N, Shaik IH, Mehvar R, McMurtry IF, Oka M, Nozik-Grayck E, Komatsu M, Ahsan F.

J Control Release. 2013 Apr 28;167(2):189-99. doi: 10.1016/j.jconrel.2013.01.011.

20.

Rho kinase-mediated vasoconstriction in pulmonary hypertension.

McMurtry IF, Abe K, Ota H, Fagan KA, Oka M.

Adv Exp Med Biol. 2010;661:299-308. doi: 10.1007/978-1-60761-500-2_19. Review.

PMID:
20204738

Supplemental Content

Support Center